Skip to main content
Erschienen in:

27.10.2024 | Research

Predictors for spontaneous remission in childhood chronic immune thrombocytopenia

verfasst von: Yuan-Ning Yang, Yun-Hsuan Yeh, Jiann-Shiuh Chen, Li-Wen Chen, Yung-Chieh Lin, Chao-Neng Cheng

Erschienen in: Annals of Hematology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

This study examined the factors associated with spontaneous remission in children with chronic immune thrombocytopenia (ITP). We retrospectively analyzed the medical records of patients diagnosed with ITP from January 1988 to December 2019 at our institute. A total of 104 children with chronic ITP were identified. The median follow-up time from diagnosis of chronic ITP was 3.6 years (IQR 1.2–8.3, range 0.1–31.4). Fifteen (14.4%) patients with severe symptoms received specific platelet-elevating therapies, including splenectomy, rituximab, and thrombopoietin receptor agonists. Seven of them achieved remission. Among the patients with a platelet count < 30 × 109/L at the time of diagnosis of chronic ITP, those who received specific platelet-elevating therapies had a higher remission rate compared to those who did not (HR: 4.66, 95% CI: 1.36–16.0). Sixteen patients (15.4%) developed systemic lupus erythematosus, 46 (44.2%) still had thrombocytopenia after a median follow-up of 6.8 years, and 42 (40.4%) achieved remission with a median time to remission of 2.0 years (IQR 0.6–4.1, range 0.1–15.7). The two independent predictive factors for spontaneous remission in childhood chronic ITP were platelet counts > 30 × 109/L at the time of diagnosis of chronic ITP (HR: 3.16, 95% CI: 1.51–6.62) and persistently negative ANA at follow-up (HR: 6.12, 95% CI: 1.46–25.7). The cumulative probabilities of spontaneous remission at 10 years post-diagnosis of chronic ITP were 72.2% for patients without risk factor compared to 0% for patients with two risk factors.
Literatur
1.
Zurück zum Zitat Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393. https://doi.org/10.1182/blood-2008-07-162503CrossRefPubMed Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393. https://​doi.​org/​10.​1182/​blood-2008-07-162503CrossRefPubMed
4.
Zurück zum Zitat Donato H, Picon A, Martinez M, Rapetti MC, Rosso A, Gomez S, Rossi N, Bacciedoni V, Schvartzman G, Riccheri C, Costa A, Di Santo J (2009) Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer 52(4):491–496. https://doi.org/10.1002/pbc.21872CrossRefPubMed Donato H, Picon A, Martinez M, Rapetti MC, Rosso A, Gomez S, Rossi N, Bacciedoni V, Schvartzman G, Riccheri C, Costa A, Di Santo J (2009) Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer 52(4):491–496. https://​doi.​org/​10.​1002/​pbc.​21872CrossRefPubMed
8.
Zurück zum Zitat Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM (2019) Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol 94(7):741–750. https://doi.org/10.1002/ajh.25479CrossRefPubMedPubMedCentral Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM (2019) Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol 94(7):741–750. https://​doi.​org/​10.​1002/​ajh.​25479CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Shimano KA, Neunert C, Bussel JB, Klaassen RJ, Bhat R, Pastore YD, Lambert MP, Bennett CM, Despotovic JM, Forbes P, Grace RF (2021) Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. Pediatr Blood Cancer 68(6):e29023. https://doi.org/10.1002/pbc.29023CrossRefPubMed Shimano KA, Neunert C, Bussel JB, Klaassen RJ, Bhat R, Pastore YD, Lambert MP, Bennett CM, Despotovic JM, Forbes P, Grace RF (2021) Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. Pediatr Blood Cancer 68(6):e29023. https://​doi.​org/​10.​1002/​pbc.​29023CrossRefPubMed
12.
Zurück zum Zitat Miano M, Ramenghi U, Russo G, Rubert L, Barone A, Tucci F, Farruggia P, Petrone A, Mondino A, Lo Valvo L, Crescenzio N, Bellia F, Olivieri I, Palmisani E, Caviglia I, Dufour C, Fioredda F (2016) Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol 175(3):490–495. https://doi.org/10.1111/bjh.14261CrossRefPubMed Miano M, Ramenghi U, Russo G, Rubert L, Barone A, Tucci F, Farruggia P, Petrone A, Mondino A, Lo Valvo L, Crescenzio N, Bellia F, Olivieri I, Palmisani E, Caviglia I, Dufour C, Fioredda F (2016) Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol 175(3):490–495. https://​doi.​org/​10.​1111/​bjh.​14261CrossRefPubMed
13.
Zurück zum Zitat Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF (2016) Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 study. Pediatr Blood Cancer 63(8):1407–1413. https://doi.org/10.1002/pbc.26003CrossRefPubMedPubMedCentral Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF (2016) Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 study. Pediatr Blood Cancer 63(8):1407–1413. https://​doi.​org/​10.​1002/​pbc.​26003CrossRefPubMedPubMedCentral
14.
15.
Zurück zum Zitat Ducassou S, Gourdonneau A, Fernandes H, Leverger G, Pasquet M, Fouyssac F, Bayart S, Bertrand Y, Michel G, Jeziorski E, Thomas C, Abouchallah W, Viard F, Guitton C, Cheikh N, Pellier I, Carausu L, Droz C, Leblanc T, Aladjidi N (2020) Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. Br J Haematol 189(5):931–942. https://doi.org/10.1111/bjh.16448CrossRefPubMed Ducassou S, Gourdonneau A, Fernandes H, Leverger G, Pasquet M, Fouyssac F, Bayart S, Bertrand Y, Michel G, Jeziorski E, Thomas C, Abouchallah W, Viard F, Guitton C, Cheikh N, Pellier I, Carausu L, Droz C, Leblanc T, Aladjidi N (2020) Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. Br J Haematol 189(5):931–942. https://​doi.​org/​10.​1111/​bjh.​16448CrossRefPubMed
16.
Zurück zum Zitat Ducassou S, Fernandes H, Savel H, Bertrand Y, Leblanc T, Abou Chahla W, Pasquet M, Leverger G, Barlogis V, Thomas C, Bayart S, Pellier I, Armari-Alla C, Guitton C, Cheikh N, Kherfellah D, Vassal G, Thiébaut R, Laghouati S, Aladjidi N (2021) Prospective evaluation of the first option, second-line therapy in Childhood Chronic Immune Thrombocytopenia: splenectomy or Immunomodulation. J Pediatr 231:223–230. https://doi.org/10.1016/j.jpeds.2020.12.018CrossRefPubMed Ducassou S, Fernandes H, Savel H, Bertrand Y, Leblanc T, Abou Chahla W, Pasquet M, Leverger G, Barlogis V, Thomas C, Bayart S, Pellier I, Armari-Alla C, Guitton C, Cheikh N, Kherfellah D, Vassal G, Thiébaut R, Laghouati S, Aladjidi N (2021) Prospective evaluation of the first option, second-line therapy in Childhood Chronic Immune Thrombocytopenia: splenectomy or Immunomodulation. J Pediatr 231:223–230. https://​doi.​org/​10.​1016/​j.​jpeds.​2020.​12.​018CrossRefPubMed
17.
Zurück zum Zitat Pincez T, Aladjidi N, Héritier S, Garnier N, Fahd M, Abou Chahla W, Fernandes H, Dichamp C, Ducassou S, Pasquet M, Bayart S, Moshous D, Cheikh N, Paillard C, Plantaz D, Jeziorski E, Thomas C, Guitton C, Deparis M, Marie Cardine A, Stephan JL, Pellier I, Doré E, Benadiba J, Pluchart C, Briandet C, Barlogis V, Leverger G, Leblanc T (2022) Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias. Blood 140(3):253–261. https://doi.org/10.1182/blood.2022015508CrossRefPubMed Pincez T, Aladjidi N, Héritier S, Garnier N, Fahd M, Abou Chahla W, Fernandes H, Dichamp C, Ducassou S, Pasquet M, Bayart S, Moshous D, Cheikh N, Paillard C, Plantaz D, Jeziorski E, Thomas C, Guitton C, Deparis M, Marie Cardine A, Stephan JL, Pellier I, Doré E, Benadiba J, Pluchart C, Briandet C, Barlogis V, Leverger G, Leblanc T (2022) Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias. Blood 140(3):253–261. https://​doi.​org/​10.​1182/​blood.​2022015508CrossRefPubMed
19.
Zurück zum Zitat Chotsampancharoen T, Sripornsawan P, Duangchoo S, Wongchanchailert M, McNeil E (2017) Clinical outcome of childhood chronic immune thrombocytopenia: a 38-year experience from a single tertiary center in Thailand. Pediatr Blood Cancer 64(11):e26598. https://doi.org/10.1002/pbc.26598CrossRef Chotsampancharoen T, Sripornsawan P, Duangchoo S, Wongchanchailert M, McNeil E (2017) Clinical outcome of childhood chronic immune thrombocytopenia: a 38-year experience from a single tertiary center in Thailand. Pediatr Blood Cancer 64(11):e26598. https://​doi.​org/​10.​1002/​pbc.​26598CrossRef
27.
Zurück zum Zitat Pincez T, Fernandes H, Pasquet M, Abou Chahla W, Granel J, Héritier S, Fahd M, Ducassou S, Thomas C, Garnier N, Barlogis V, Jeziorski E, Bayart S, Chastagner P, Cheikh N, Guitton C, Paillard C, Lejeune J, Millot F, Li-Thiao Te V, Mallebranche C, Pellier I, Neven B, Armari-Alla C, Carausu L, Piguet C, Benadiba J, Pluchart C, Stephan JL, Deparis M, Briandet C, Doré E, Marie-Cardine A, Leblanc T, Leverger G, Aladjidi N (2023) Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia. Am J Hematol. https://doi.org/10.1002/ajh.26900CrossRefPubMed Pincez T, Fernandes H, Pasquet M, Abou Chahla W, Granel J, Héritier S, Fahd M, Ducassou S, Thomas C, Garnier N, Barlogis V, Jeziorski E, Bayart S, Chastagner P, Cheikh N, Guitton C, Paillard C, Lejeune J, Millot F, Li-Thiao Te V, Mallebranche C, Pellier I, Neven B, Armari-Alla C, Carausu L, Piguet C, Benadiba J, Pluchart C, Stephan JL, Deparis M, Briandet C, Doré E, Marie-Cardine A, Leblanc T, Leverger G, Aladjidi N (2023) Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia. Am J Hematol. https://​doi.​org/​10.​1002/​ajh.​26900CrossRefPubMed
28.
Zurück zum Zitat Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115(2):168–186. https://doi.org/10.1182/blood-2009-06-225565CrossRefPubMed Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115(2):168–186. https://​doi.​org/​10.​1182/​blood-2009-06-225565CrossRefPubMed
34.
Zurück zum Zitat Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, Gonzalez-Lopez TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780–3817. https://doi.org/10.1182/bloodadvances.2019000812CrossRefPubMedPubMedCentral Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, Gonzalez-Lopez TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780–3817. https://​doi.​org/​10.​1182/​bloodadvances.​2019000812CrossRefPubMedPubMedCentral
Metadaten
Titel
Predictors for spontaneous remission in childhood chronic immune thrombocytopenia
verfasst von
Yuan-Ning Yang
Yun-Hsuan Yeh
Jiann-Shiuh Chen
Li-Wen Chen
Yung-Chieh Lin
Chao-Neng Cheng
Publikationsdatum
27.10.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 12/2024
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-06056-5

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.